RE:RE:RE:RE:RE:RE:RE:RE:Teuto or Verdemed? I can't picture the company being for sale, selling near these levels would be suicide for BOD ... at the current share count, MPL needs to be between $1-$1.50/ share before they can consider selling the company. Governments are finally on board, and the leglislative changes that we've been waiting for are finally starting (including upcoming US rescheduling).
I think Strachan moving to the BOD is for the following:
1A) Redudant position - they are too small to need a CEO & President
1B) Ineffective & expensive - does anyone really think that Keith was worth the $850K he made last year? I definitely don't, he's a glorified sales rep that has no business being in the C-suite. Moving him to the board hopefully was a compromise on his severance package
2) M&A - MPL acquires a similar size company and the target CEO is a better fit in the role
thoughts?